Khan Mohd, Sherwani Subuhi, Khan Saif, Alouffi Sultan, Alam Mohammad, Al-Motair Khalid, Khan Shahper
Department of Chemistry, College of Sciences, University of Ha'il, Ha'il 2440, Saudi Arabia.
Molecular Diagnostic and Personalised Therapeutics Unit, University of Ha'il, Ha'il 2440, Saudi Arabia.
Molecules. 2021 Apr 14;26(8):2262. doi: 10.3390/molecules26082262.
Glioblastoma (GB) is an aggressive cancer with high microvascular proliferation, resulting in accelerated invasion and diffused infiltration into the surrounding brain tissues with very low survival rates. Treatment options are often multimodal, such as surgical resection with concurrent radiotherapy and chemotherapy. The development of resistance of tumor cells to radiation in the areas of hypoxia decreases the efficiency of such treatments. Additionally, the difficulty of ensuring drugs effectively cross the natural blood-brain barrier (BBB) substantially reduces treatment efficiency. These conditions concomitantly limit the efficacy of standard chemotherapeutic agents available for GB. Indeed, there is an urgent need of a multifunctional drug vehicle system that has potential to transport anticancer drugs efficiently to the target and can successfully cross the BBB. In this review, we summarize some nanoparticle (NP)-based therapeutics attached to GB cells with antigens and membrane receptors for site-directed drug targeting. Such multicore drug delivery systems are potentially biodegradable, site-directed, nontoxic to normal cells and offer long-lasting therapeutic effects against brain cancer. These models could have better therapeutic potential for GB as well as efficient drug delivery reaching the tumor milieu. The goal of this article is to provide key considerations and a better understanding of the development of nanotherapeutics with good targetability and better tolerability in the fight against GB.
胶质母细胞瘤(GB)是一种侵袭性癌症,微血管增殖高,导致侵袭加速并扩散浸润到周围脑组织,生存率极低。治疗方案通常是多模式的,如手术切除并同时进行放疗和化疗。肿瘤细胞在缺氧区域对辐射产生抗性,降低了此类治疗的效率。此外,确保药物有效穿过天然血脑屏障(BBB)的难度大大降低了治疗效率。这些情况共同限制了可用于GB的标准化疗药物的疗效。确实,迫切需要一种多功能药物载体系统,它有潜力将抗癌药物有效地输送到靶点,并能成功穿过血脑屏障。在这篇综述中,我们总结了一些基于纳米颗粒(NP)的疗法,这些疗法通过抗原和膜受体附着于GB细胞,用于定点药物靶向。这种多核药物递送系统可能具有生物可降解性、定点性、对正常细胞无毒,并对脑癌具有持久的治疗效果。这些模型对GB可能具有更好的治疗潜力,以及能有效将药物递送至肿瘤环境。本文的目的是提供关键考量因素,并更好地理解在对抗GB中具有良好靶向性和更好耐受性的纳米疗法的发展。